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as fixed effects and baseline value as covariate. The model was chosen in accord-
ance with the pre-specified model for the clinical trial. Results: SF-36 estimated 
treatment differences (ETD; IDegLira–IGlar), at EOT were 1.9 points [95% CI: 0.8; 3.1] 
(p< 0.001) and –0.1 points [95% CI: –1.5; 1.3] (NS) for physical and mental component 
summary scores, respectively. Mean EQ-5D score ± SD at baseline was 0.901 ± 0.083. 
At EOT mean EQ-5D score ± SD was 0.915 ± 0.070 and 0.903 ± 0.084 for IDegLira and 
IGlar, respectively; ETD 0.017 points [95% CI: 0.007; 0.026] (p= 0.001). ConClusions: 
This analysis suggests that IDegLira provides a statistically significant improvement 
in health utility compared with IGlar, in patients with T2D inadequately controlled 
on IGlar and metformin. The health utility improvement was generally driven by 
improvement in physical health, while mental health remained stable.
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objeCtives: Data on wastage behaviours of patients with diabetes taking mealtime 
insulin (MTI) with a prefilled disposable pen or reusable pen with disposable car-
tridge are lacking. A patient survey was undertaken to estimate the average number 
of MTI units discarded per pen/cartridge by patients with diabetes taking > 20 units/
day, based on injection habits when insufficient insulin remains in a pen/cartridge 
to administer a full dose in a single injection. Methods: Cross-sectional, online, 
self-reported survey of MTI usage and wastage behaviours in adults with type 1 or 
2 diabetes [T1D, T2D] using > 20 units/day of MTI administered via 100 units/mL 
pen/cartridge for ≥ 1 month, conducted between February and March 2015 in four 
EU countries [France, Germany, Italy, United Kingdom]. Results: 400 patients with 
diabetes [120 T1D; 280 T2D] completed the survey. Mean age (SD) was 54.5 (12.2) years 
[T1D: 50.3 (13.0); T2D: 56.3 (11.4)]. Average BMI was 29.9 (7.2) kg/m2 [T1D: 26.9 (4.9); 
T2D: 31.3 (7.7)]. Average time since diabetes diagnosis was 16.1 (11.7) years [T1D: 23.4 
(14.2); T2D: 13.0 (8.8)]. Total average MTI units taken per day (self-reported number 
of units taken at breakfast, lunch and dinner combined) was 54.8 (34.1) units [T1D: 
41.1 (21.9); T2D: 60.6 (36.7)]. 255 patients [63.8%] reported wasting no insulin, whereas 
145 patients [36.3%] reported wasting some insulin. Overall, patients reported dis-
carding 2.0 [95% CI 1.4–2.5] pens/cartridges per month on average that still had 
insulin remaining. Patients who reported wasting some insulin discarded on average 
8.6 [95% CI 7.2–10.0] units of MTI per pen/cartridge. ConClusions: One third of 
patients taking > 20 units/day MTI reported discarding at least one 100 units/mL pen/
cartridge with insulin remaining. These results suggest there may be an opportunity 
to reduce insulin wastage with new higher strength MTI formulations that provide 
more total units per pen and fewer pen/cartridge transitions.
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objeCtives: To investigate the frequency of hypoglycaemic episodes and its effect 
on diabetes management, healthcare resource use, economic burden and time loss 
(including time loss from work and daily life) for insulin-treated diabetes patients in 
urban China. Methods: A questionnaire was used to collect data from 7 third-grade 
class-A hospitals in Beijing, Nanjing, Chengdu, Kunming and Ha’erbin in China from 
July to September of 2012. Type 1 and type 2 diabetes patients treated with insulin 
were included. Hypoglycaemia episodes were categorized as mild (symptoms could 
be self-disappeared), moderate (symptoms could not be self-disappeared), severe 
(coma happen, usually require medical assistance) and nocturnal (occur during 
sleep, including mild, moderate and severe) hypoglycaemia. Descriptive Statistic 
analysis was applied to the data. Results: More than half (56.7%) of 602 enrolled 
patients reported experiencing hypoglycaemia. 34.7%, 3.3% and 3.5% patients 
reported mild, moderate and nocturnal hypoglycaemia during the preceding month, 
with a total of 593, 84.5 and 45.5 episodes, respectively. 9 patients reported 12 severe 
hypoglycaemia episodes during the preceding year. Among patients experiencing 
hypoglycaemia, 15.5% reported anxiety of anti-diabetes drugs, 16.1% reported 
treatment regimens modification by themselves and 12.6% by their doctors, 19.9% 
reported extra self-monitoring of blood glucose of 3.14 times/week, 11.7% reported 
time loss by an average of 2 days/event, and 9.4% reported time loss for family 
members by an average of 1.89 days/event. Of the patients experiencing severe 
hypoglycaemia, 28.6% required emergency visit and 14.3% required hospitalization. 
Of patients experiencing nocturnal hypoglycaemia, 5.3% required hospitalization. 
Patients experiencing hypoglycaemia reported an average of hypoglycaemia-related 
cost of 44.06CNY/month. Nevertheless, for those who required medical assistance, 
the medical cost was 1216.53 CNY/event. ConClusions: Hypoglycaemia was com-
mon in diabetes patients treated with insulin. Hypoglycaemia had negative impact 
on diabetes management and was associated with increasing healthcare utilization, 
economic burden and time loss for patients and family.
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objeCtives: An adequate disease-related knowledge is important in treatment 
and management of ailments. Within this context, patients are needed to have 
for a better control of diabetes. ConClusions: The responses of patients with 
both types of diabetes clearly show the need for new management approaches 
to alleviate the burden associated with the disease addressing the specific unmet 
needs of diabetic patients.
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objeCtives: To use a discrete choice experiment (DCE) to evaluate preferences for 
the actual treatment features and overall profiles of two injectable glucagon-like 
peptide-1 (GLP-1) receptor agonists (dulaglutide and liraglutide) among patients 
with type 2 diabetes (T2DM) in the United Kingdom (UK). Methods: In-person 
interviews were conducted in the UK to administer a DCE to patients with self-
reported T2DM, naïve to treatment with injectable medications. The DCE examined 
6 attributes of T2DM treatment each described by 2 levels: ‘dosing frequency,’ ‘HbA1c 
change,’ ‘weight change,’ ‘type of delivery system,’ ‘frequency of nausea,’ and ‘fre-
quency of hypoglycemia.’ Part-worth utilities were estimated using random effects 
logit models and used to calculate relative importance values for each attribute. A 
Chi-square test was used to determine differences in preferences for dulaglutide vs. 
liraglutide profiles. Results: A total of 243 participants [mean age: 60.5 (SD 10.9) 
years; 76.1% male; mean BMI: 29.8 (SD 5.4) kg/m2] completed the study. Relative 
importance values for the attributes in rank order were: ‘dosing frequency’ (41.6%), 
‘type of delivery system’ (35.5%), ‘frequency of nausea’ (10.4%), ‘weight change’ 
(5.9%), ‘HbA1c change’ (3.6%), and ‘frequency of hypoglycemia’ (3.0%). Significantly 
more participants preferred the dulaglutide profile (83.1%) compared to the liraglu-
tide profile (16.9%; p< 0.0001). ConClusions: This study elicited patients’ prefer-
ences for attributes and levels representing the actual characteristics of two specific 
GLP-1 medications. In this context, dosing frequency and type of delivery system 
were most important, accounting for over 75% of the relative importance. While 
previous studies have identified efficacy as highly important in T2DM medication 
decisions, this study suggests that when differences in efficacy between medica-
tions are small, other treatment features (e.g., dosing frequency and delivery system) 
are of much greater importance to patients.
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objeCtives: Understanding the preferences for attributes of T2DM treatments 
among patients in Spain. Methods: Patients in Spain (self-reported physician 
diagnosis of T2DM, taking a prescription T2DM medication for > 2 years) com-
pleted an online discrete-choice experiment (DCE) survey (funded by GSK) to elicit 
preferences for T2DM treatment attributes. Respondents chose between pairs 
of hypothetical T2DM treatments defined by seven attributes: chance of reach-
ing target HbA1c, reduction in risk of serious heart attack or stroke, frequency 
of hypoglycemia, risk of gastrointestinal (GI) problems, weight change, mode of 
administration, and dosing frequency. Random-parameters logit (RPL) was used 
to analyze the data. Minimum acceptable benefit (MAB) was calculated with RPL 
coefficients and measures the percentage point (pp) increase in the probability of 
reaching target HbA1c that respondents require in order to accept worse levels of 
other attributes. Results: 401 patients responded (mean age 51, 77% male, 33% 
diagnosed more than 7 years ago). The DCE respondents preferred pills to injections 
and once-weekly dosing over other schedules. The highest MAB levels were: moving 
from pill to injection (MAB= 59pp), moving from once-weekly dosing frequency to 
more than twice a day (MAB= 40pp), moving from no risk of GI problems to 30% risk 
of GI problems (MAB= 37pp), moving from no hypos to more than 2 hypos per month 
(MAB= 37pp), and moving from a 2-kg weight loss to a 2-kg weight gain (MAB= 35pp). 
Respondents using injectables were indifferent between pills and injections, while 
respondents not using injectables had a strong preference for pills over injections 
(P = 0.00). ConClusions: Respondents were willing to trade-off efficacy for an 
improvement in mode of administration (from injection to pills) and improved side 
effects . Given the variety of T2DM medications available, the results suggest that 
careful discussion about patient preferences could help improve patient satisfac-
tion with T2DM drugs.
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objeCtives: This analysis of data from the DUAL V clinical trial compared health 
utility scores of IDegLira, a fixed-ratio combination of insulin degludec and liraglu-
tide, with insulin glargine (IGlar) in patients with type 2 diabetes (T2D). Methods: 
Health status data were collected using the Short-Form 36 v2 (SF-36) questionnaire 
during a 26-week, multinational, multi-centre, open-label, parallel, randomised, 
treat-to-target trial comparing IDegLira (n= 278) with IGlar (n= 279) (either treat-
ment given once daily in addition to metformin) in patients with T2D, inadequately 
controlled on IGlar (20–50 units daily) and metformin (Buse et al. Diabetes 2015; 64 
(Suppl. 1):A43–A44; abstract 166-OR). In this post hoc analysis, SF-36 scores were 
mapped to the EuroQol-5D (EQ-5D) health utility scale using a validated algorithm 
(Model 3; Rowen et al. Health Qual Life Outcomes 2009;7:27). EQ-5D scores at end 
of trial (EOT) were analysed using an ANCOVA model with treatment and region 
